Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
Commentary|Videos|March 19, 2026
Looking Towards the Future of Clinical Trials in Gynecologic Oncology
Author(s)John Moroney, MD, Katherine Kurnit, MD
Fact checked by: Kyle Doherty
John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss which future advances being examined in clinical trials in gynecologic oncology are catching their eyes.
Advertisement
John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss notable ongoing clinical trials in gynecologic oncology at the University of Chicago and beyond. They underscore that many of the most interesting approaches being examined are immunotherapy-based and also highlight trials using cellular therapies.
Advertisement
Related to this article
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.
EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.
IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
4
Dr Graham on Data for JNJ-87189401 Plus Pasritamig in mCRPC
5